NeuroOne Medical Technologies, a medical device company utilizing a proprietary thin-film platform, outlined its strategic focus on expanding into spinal cord stimulation and neurological treatment markets at the Moody Capital Disruptive Growth & Life Science Conference in September 2026. The company, valued at approximately $15 million with a $2 million cash position and no debt, reported a recent stock decline of 65% over six months, trading near its 52-week low of $1.42 per share. Despite this downturn, NeuroOne’s leadership emphasized operational momentum, citing strong backlog and clinical adoption as key drivers for the upcoming quarter, according to remarks by Chief Business Officer David Wambeke and CEO Dave Rosa.
The company’s revenue guidance for fiscal 2026 ranges from $9.2 million to $10.5 million, with Zimmer Biomet contributing about $9 million to $10 million of that total. Zimmer Biomet, a $16 billion market-cap company, is a major distribution partner for NeuroOne’s ROSA ONE Brain robot. To date, Zimmer Biomet has generated $8.5 million in licensing revenue for NeuroOne. Wambeke disclosed a $700,000 personal investment in the company, underscoring confidence in its growth trajectory.
NeuroOne’s technology platform includes four FDA 510(k)-cleared devices, including a basivertebral nerve ablation system, which it claims reduces procedural time for BVNA—currently a $200 million market—from 10 minutes to just five minutes per lesion. The company’s CT-based approach also aims to cut procedure duration for epilepsy and trigeminal neuralgia treatments from 12 hours to under four hours, enabling more efficient patient care. Clinical data from early adopters, including the Cleveland Clinic, have shown success, such as an 18-year-old patient with drug-resistant epilepsy achieving seizure freedom for a year after treatment with the OneRF Ablation System.
Competitive pressures remain intense. ClearPoint Neuro, a $500 million market-cap competitor, treats around 6,000 patients annually at $1.5 million per patient. Meanwhile, Medtronic and Stryker are entering the BVNA market, while Boston Scientific’s acquisition of Relievant Medsystems—another BVNA leader—has intensified rivalry. The broader spinal cord stimulation market is valued at $3 billion, with NeuroOne positioning itself to capitalize on unmet needs in drug-resistant epilepsy and chronic pain management.
The company’s patent portfolio, which includes 13 issued and pending patents, extends its intellectual property globally, while its devices can remain implanted in the brain for up to 30 days. Strategic partnerships with early-investor neurologists at institutions like the Mayo Clinic further bolster its clinical credibility. With analyst price targets ranging from $5 to $8.80 and a projected negative earnings per share of $1.03 for 2026, NeuroOne’s growth hinges on scaling its backlog, refining its technology, and expanding into adjacent markets such as gene therapy, where companies like uniQure are making inroads in treating Huntington’s disease with potential annual revenue of up to $2 billion if approved.
Despite its current valuation, NeuroOne’s thin-film technology offers a differentiated approach to traditional drug-delivery methods, positioning it as a disruptive player in a rapidly evolving medical device landscape.
